Overview

Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334

Status:
Completed
Trial end date:
2020-02-04
Target enrollment:
Participant gender:
Summary
This is a first in human (FIH), single-centre, double -blind, randomised, cross-over, SAD followed by a MAD study of IZD334 conducted in healthy adult participants as well as an open-label cohort in adult patients with CAPS. The study is designed to evaluate the safety, tolerability, PK, PD, and food effect of IZD334 in healthy adult participants, and to evaluate the safety, tolerability, PK, PD, and preliminary clinical efficacy of IZD334 in adult patients with CAPS.
Phase:
Phase 1
Details
Lead Sponsor:
Inflazome UK Ltd